CoChat

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines

Open access
Klein, Christian, Waldhauer, Inja, Nicolini, Valeria G., Freimoser-Grundschober, Anne, Nayak, Tapan, Vugts, Danielle J., Dunn, Claire, Bolijn, Marije, Benz, Jörg, Stihle, Martine, Lang, Sabine, Roemmele, Michaele, Hofer, Thomas, van Puijenbroek, Erwin, Wittig, David, Moser, Samuel, Ast, Oliver, Brünker, Peter, Gorr, Ingo H., Neumann, Sebastian, de Vera Mudry, Maria Cristina, Hinton, Heather, Crameri, Flavio, Saro, Jose, Evers, Stefan, Gerdes, Christian, Bacac, Marina, van Dongen, Guus, Moessner, Ekkehard, Umaña, Pablo · 2017 · OncoImmunology

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.

Abstract

We developed cergutuzumab amunaleukin (CEA-IL2v, RG7813), a novel monomeric CEA-targeted immunocytokine, that comprises a single IL-2 variant (IL2v) moiety with abolished CD25 binding, fused to the C-terminus of a high affinity, bivalent carcinoembryonic antigen (CEA)-specific antibody devoid of Fc-mediated effector functions. Its molecular design aims to (i) avoid preferential activation of regulatory T-cells vs. immune effector cells by removing CD25 binding; (ii) increase the therapeutic index of IL-2 therapy by (a) preferential retention at the tumor by having a lower dissociation rate from CEA-expressing cancer cells vs. IL-2R-expressing cells, (b) avoiding any FcγR-binding and Fc effector functions and (c) reduced binding to endothelial cells expressing CD25; and (iii) improve the pharmacokinetics, and thus convenience of administration, of IL-2. The crystal structure of the IL2v-IL-2Rβγ complex was determined and CEA-IL2v activity was assessed using human immune effector cells. Tumor targeting was investigated in tumor-bearing mice using 89Zr-labeled CEA-IL2v. Efficacy studies were performed in (a) syngeneic mouse models as monotherapy and combined with anti-PD-L1, and in (b) xenograft mouse models in combination with ADCC-mediating antibodies. CEA-IL2v binds to CEA with pM avidity but not to CD25, and consequently did not preferentially activate Tregs. In vivo, CEA-IL2v demonstrated superior pharmacokinetics and tumor targeting compared with a wild-type IL-2-based CEA immunocytokine (CEA-IL2wt). CEA-IL2v strongly expanded NK and CD8+ T cells, skewing the CD8+:CD4+ ratio toward CD8+ T cells both in the periphery and in the tumor, and mediated single agent efficacy in syngeneic MC38-CEA and PancO2-CEA models. Combination with trastuzumab, cetuximab and imgatuzumab, all of human IgG1 isotype, resulted in superior efficacy compared with the monotherapies alone. Combined with anti-PD-L1, CEA-IL2v mediated superior efficacy over the respective monotherapies, and over the combination with an untargeted control immunocytokine. These preclinical data support the ongoing clinical investigation of the cergutuzumab amunaleukin immunocytokine with abolished CD25 binding for the treatment of CEA-positive solid tumors in combination with PD-L1 checkpoint blockade and ADCC competent antibodies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/2162402x.2016.1277306

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. (A) IL2v/IL-2Rβγ complex structure. IL2v is shown yellow, the mutations in blue. The IL-2Rβ chain is colored in cyan and the γc chain in magenta. (B) Close-up view onto the loop region between helix A and helix B and the binding site of IL-2 with IL-2Rα. The picture shows an overlay of the IL2v-IL-2Rβγ (yellow) structure with 2B5I (gray representation). Mutations in the two hydrophobic patches with F42A, Y45A and L72G are highlighted in blue and circled. (C) Superposition of all atoms of IL2v-IL-2Rβγ with the quaternary complex IL-2, IL-2Rα, IL-2Rβ, γc (2erj). IL2v-IL-2Rβγ is colored as in Fig. 1A. 2B5I is shown in gray. (D) Schematic representation of CEA-IL2v and its key design features.
Figure 1. (A) IL2v/IL-2Rβγ complex structure. IL2v is shown yellow, the mutations in blue. The IL-2Rβ chain is colored in cyan and the γc chain in magenta. (B) Close-up view onto the loop region between helix A and helix B and the binding site of IL-2 with IL-2Rα. The picture shows an overlay of the IL2v-IL-2Rβγ (yellow) structure with 2B5I (gray representation). Mutations in the two hydrophobic patches with F42A, Y45A and L72G are highlighted in blue and circled. (C) Superposition of all atoms of IL2v-IL-2Rβγ with the quaternary complex IL-2, IL-2Rα, IL-2Rβ, γc (2erj). IL2v-IL-2Rβγ is colored as in Fig. 1A. 2B5I is shown in gray. (D) Schematic representation of CEA-IL2v and its key design features.CC BY-NC-ND · PubMed Central
Figure 2. (A–D) FACS analysis of STAT5 phosphorylation on (A) Treg cells (CD4+CD25+FOXP3+), (B) CD4+ T cells (CD4+CD25−), C) CD8+ T cells (CD3+CD8+) and (D) NK cells (CD3−CD56+) within freshly isolated PBMCs 20 min after treatment with CEA-IL2v, CEA-IL2wt and aldesleukin; (E–H) Fas-mediated apoptosis induction (E, F) and proliferation (G, H) of CD4+ and CD8+ T cells following treatment with CEA-IL2v and CEA-IL2wt after overnight pre-activation with PHA. Exemplary data from ≥ 3 independent experiments. Shown are means from triplicates and standard deviation.
Figure 2. (A–D) FACS analysis of STAT5 phosphorylation on (A) Treg cells (CD4+CD25+FOXP3+), (B) CD4+ T cells (CD4+CD25−), C) CD8+ T cells (CD3+CD8+) and (D) NK cells (CD3−CD56+) within freshly isolated PBMCs 20 min after treatment with CEA-IL2v, CEA-IL2wt and aldesleukin; (E–H) Fas-mediated apoptosis induction (E, F) and proliferation (G, H) of CD4+ and CD8+ T cells following treatment with CEA-IL2v and CEA-IL2wt after overnight pre-activation with PHA. Exemplary data from ≥ 3 independent experiments. Shown are means from triplicates and standard deviation.CC BY-NC-ND · PubMed Central
Figure 3. (A) Mean plasma concentration-time profiles of CEA antibody CH1A1A1–2F1, CEA-IL2v and CEA- IL2wt in CEA-transgenic C57BL/6 mice as determined by ELISA. (B) Organ biodistribution of 89Zr-CEA-IL2v 3 d after injection at different doses in immunocompetent CEA-transgenic C57BL/6 mice bearing syngeneic CEA-positive MC38-CEA tumors and CEA-negative MC38 tumors on contra-lateral site. All values are expressed as %ID/g. Data represent mean value ± SD from at least four determinations. (C) Standardized Uptake Values (SUVs) of tumors derived from PET imaging of immunocompetent CEA-transgenic C57BL/6 mice bearing syngeneic CEA-positive MC38-CEA tumors after injection of 89Zr-CEA-IL2v or 89Zr-CEA-IL2wt. Data represent mean value ± SD from at least four determinations. (D) Biodistribution of 89Zr-CEA-IL2v compared with 89Zr-CEA-IL2wt 4 d after injection in immunocompetent CEA-transgenic C57BL/6 mice bearing syngeneic MC38-CE tumors. Data represent mean value ± SD from > 4 determinations.
Figure 3. (A) Mean plasma concentration-time profiles of CEA antibody CH1A1A1–2F1, CEA-IL2v and CEA- IL2wt in CEA-transgenic C57BL/6 mice as determined by ELISA. (B) Organ biodistribution of 89Zr-CEA-IL2v 3 d after injection at different doses in immunocompetent CEA-transgenic C57BL/6 mice bearing syngeneic CEA-positive MC38-CEA tumors and CEA-negative MC38 tumors on contra-lateral site. All values are expressed as %ID/g. Data represent mean value ± SD from at least four determinations. (C) Standardized Uptake Values (SUVs) of tumors derived from PET imaging of immunocompetent CEA-transgenic C57BL/6 mice bearing syngeneic CEA-positive MC38-CEA tumors after injection of 89Zr-CEA-IL2v or 89Zr-CEA-IL2wt. Data represent mean value ± SD from at least four determinations. (D) Biodistribution of 89Zr-CEA-IL2v compared with 89Zr-CEA-IL2wt 4 d after injection in immunocompetent CEA-transgenic C57BL/6 mice bearing syngeneic MC38-CE tumors. Data represent mean value ± SD from > 4 determinations.CC BY-NC-ND · PubMed Central
Figure 4. Immuno-pharmacodynamics in tumor-free and tumor-bearing C57BL/6 mice: (A) Peripheral T and NK cell expansion by CEA-IL2v. Shown are lymphocytes in blood 7 d after a single i.v. dose of CEA-IL2v. (B) Increase in the numbers of circulating (per μL blood) and intratumoral (per g tissue) CD8+ T cells, γδ T cells and NK cells in LLC1-CEA syngeneic tumor model 5 d after injection of 0.5 or 2 mg/kg muCEA-IL2v as determined by flow cytometry (upper panels). A skewing of the T cell compartment in favor of CD8+ T cells as shown by the ratio of CD8+ T to total CD4+ T and Treg in the blood and tumors of LLC1-CEA tumor-bearing mice (lower panels). (C) Increase of CD3 T cells in LLC1-CEA syngeneic tumor model 5 d after injection of 1.0 mg/kg CEA-IL2v as determined by immunohistochemistry.
Figure 4. Immuno-pharmacodynamics in tumor-free and tumor-bearing C57BL/6 mice: (A) Peripheral T and NK cell expansion by CEA-IL2v. Shown are lymphocytes in blood 7 d after a single i.v. dose of CEA-IL2v. (B) Increase in the numbers of circulating (per μL blood) and intratumoral (per g tissue) CD8+ T cells, γδ T cells and NK cells in LLC1-CEA syngeneic tumor model 5 d after injection of 0.5 or 2 mg/kg muCEA-IL2v as determined by flow cytometry (upper panels). A skewing of the T cell compartment in favor of CD8+ T cells as shown by the ratio of CD8+ T to total CD4+ T and Treg in the blood and tumors of LLC1-CEA tumor-bearing mice (lower panels). (C) Increase of CD3 T cells in LLC1-CEA syngeneic tumor model 5 d after injection of 1.0 mg/kg CEA-IL2v as determined by immunohistochemistry.CC BY-NC-ND · PubMed Central
Figure 5. (A, B) Monotherapy efficacy: (A) Efficacy of 2 mg/kg CEA-IL2v (q1w3 starting on day 7 after tumor inocculation) as single agent in the syngeneic intrasplenic MC38-CEA model in CEA-transgenic C57/BL6 mice. (B) Efficacy of 0.5 mg/kg muCEA-IL2v (q1w3 starting on day 7 after tumor inocculation) as single agent in the syngeneic orthotopic PancO2-CEA model in CEA-transgenic C57/BL6 mice. (C, D) Combination of CEA-IL2v with PD-L1 checkpoint blockade in syngeneic models in CEA-transgenic C57BL/6 mice. (C) Efficacy of 0.25 mg/kg muCEA-IL2v (q1w5) combined with 10 mg/kg <muPD-L1> antibody 6E11 (q1w5) concomitantly starting on day 7 vs. vehicle and the respective monotherapies in the orthotopic PancO2-CEA pancreatic syngeneic model. (D) Efficacy of 0.25 mg/kg muCEA-IL2v or a matched dose of 0.2 mg/kg untargeted muDP47-IL2v control immunocytokine (q1w4) combined with 10 mg/kg <muPD-L1> antibody 6E11 (q1w4) concomitantly starting on day 7 vs. vehicle and the respective monotherapies. Pooled data from two independent studies are shown.
Figure 5. (A, B) Monotherapy efficacy: (A) Efficacy of 2 mg/kg CEA-IL2v (q1w3 starting on day 7 after tumor inocculation) as single agent in the syngeneic intrasplenic MC38-CEA model in CEA-transgenic C57/BL6 mice. (B) Efficacy of 0.5 mg/kg muCEA-IL2v (q1w3 starting on day 7 after tumor inocculation) as single agent in the syngeneic orthotopic PancO2-CEA model in CEA-transgenic C57/BL6 mice. (C, D) Combination of CEA-IL2v with PD-L1 checkpoint blockade in syngeneic models in CEA-transgenic C57BL/6 mice. (C) Efficacy of 0.25 mg/kg muCEA-IL2v (q1w5) combined with 10 mg/kg <muPD-L1> antibody 6E11 (q1w5) concomitantly starting on day 7 vs. vehicle and the respective monotherapies in the orthotopic PancO2-CEA pancreatic syngeneic model. (D) Efficacy of 0.25 mg/kg muCEA-IL2v or a matched dose of 0.2 mg/kg untargeted muDP47-IL2v control immunocytokine (q1w4) combined with 10 mg/kg <muPD-L1> antibody 6E11 (q1w4) concomitantly starting on day 7 vs. vehicle and the respective monotherapies. Pooled data from two independent studies are shown.CC BY-NC-ND · PubMed Central
Figure 6. (A–C) Combination of CEA-IL2v with ADCC competent/ADCC enhanced antibodies in human CD16-transgenic SCID mice: (A) Combination of CEA-IL2v (1 mg/kg, q1w3) with <HER2> antibody trastuzumab in N87 (25 mg/kg, q1w3) (top) and KPL4 (10 mg/kg, q1w3) (bottom) xenograft models; (B) Combination of CEA-IL2v (1 mg/kg, q1w3) with <EGFR> antibody cetuxiumab (25 mg/kg, q1w3) in A549 (top) and Ls174t (bottom) xenograft models; (C) Combination of CEA-IL2v (1 mg/kg, q1w3) with glycoengineered <EGFR> antibody imgatuzumab (25 mg/kg, q1w3) in A549 (top) and LS174t (bottom) xenograft models.
Figure 6. (A–C) Combination of CEA-IL2v with ADCC competent/ADCC enhanced antibodies in human CD16-transgenic SCID mice: (A) Combination of CEA-IL2v (1 mg/kg, q1w3) with <HER2> antibody trastuzumab in N87 (25 mg/kg, q1w3) (top) and KPL4 (10 mg/kg, q1w3) (bottom) xenograft models; (B) Combination of CEA-IL2v (1 mg/kg, q1w3) with <EGFR> antibody cetuxiumab (25 mg/kg, q1w3) in A549 (top) and Ls174t (bottom) xenograft models; (C) Combination of CEA-IL2v (1 mg/kg, q1w3) with glycoengineered <EGFR> antibody imgatuzumab (25 mg/kg, q1w3) in A549 (top) and LS174t (bottom) xenograft models.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 68 references

Research works printed but not linked: 6

  1. Kasprzak A, 2007, Folia Morphol (Warsz), 66, 159
  2. 10.1158/1078-0432.CCR-15-1696 · DOI · Paper page
  3. Van Dongen GA, 2015, Q J Nucl Med Mol Imaging, 59, 18
  4. Clarke P, 1998, Cancer Res, 58, 1469
  5. Losey HC, 2001, Cancer Res 2015, 75
  6. Perk LR, 2005, J Nucl Med, 46, 1898

Cited by

See all 281

Metadata

Authors
Klein, C., Waldhauer, I., Nicolini, V. G., Freimoser-Grundschober, A., Nayak, T., Vugts, D. J., Dunn, C., Bolijn, M., Benz, J., Stihle, M., Lang, S., Roemmele, M., Hofer, T., van Puijenbroek, E., Wittig, D., Moser, S., Ast, O., Brünker, P., Gorr, I. H., Neumann, S., de Vera Mudry, M. C., Hinton, H., Crameri, F., Saro, J., Evers, S., Gerdes, C., Bacac, M., van Dongen, G., Moessner, E., & Umaña, P.
Affiliations
  • F. Hoffmann-La Roche AG (CH)
  • Roche Pharma Research &amp; Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland
  • Roche Pharma Research &amp; Early Development, Department of Radiology &amp; Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands
  • Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
  • Roche Pharma AG (Germany) (DE)
  • Roche Pharma Research &amp; Early Development, Roche Innovation Center Basel, Basel, Switzerland
Corresponding author
  • Klein, Christian
  • Umaña, Pablo
Venue
OncoImmunology
Published
2017-01-11
Volume
6
Issue
3
Pages
e1277306
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
OpenAlex
W2572762406
Cited by
281
References
68
Citations by year
2026: 21 · 2025: 35 · 2024: 39 · 2023: 31 · 2022: 27 · 2021: 40 · 2020: 26 · 2019: 33 · 2018: 20 · 2017: 9
FWCI
18.47
Type
journal article
Language
en
Open access
Locations
  • OncoImmunology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion, other-oa)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
  • DORA PSI (Paul Scherrer Institute) (submittedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
Funders
Genentech
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
immunocytokines, carcinoembryonic antigen, regulatory T cells, tumor targeting, pharmacokinetics, anti-PD-L1 combination therapy, antibody-dependent cellular cytotoxicity, natural killer cells, CD8+ T cells, trastuzumab, cetuximab, combination cancer immunotherapy, tumor-infiltrating lymphocytes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. https://app.cochat.ai/papers/10.1080/2162402x.2016.1277306
The paper
Klein, C., Waldhauer, I., Nicolini, V. G., Freimoser-Grundschober, A., Nayak, T., Vugts, D. J., Dunn, C., Bolijn, M., Benz, J., Stihle, M., Lang, S., Roemmele, M., Hofer, T., van Puijenbroek, E., Wittig, D., Moser, S., Ast, O., Brünker, P., Gorr, I. H., . . . Umaña, P. (2017). Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. OncoImmunology. https://doi.org/10.1080/2162402x.2016.1277306

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.